Yu Shibo, Zhu Lizhe, Xie Peiling, Jiang Siyuan, Wang Ke, Liu Yang, He Jianjun, Ren Yu
Department of Breast Surgery, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi 710061, P.R. China.
Oncol Lett. 2020 Aug;20(2):1300-1310. doi: 10.3892/ol.2020.11651. Epub 2020 May 20.
A number of studies have demonstrated the crucial functions of GINS2 within the GINS complex in various types of cancer. However, the molecular mechanisms and prognostic value of GINS2 in breast cancer remain unknown. The present study used; BC-GenExMiner, COSMIC, UCSC Xena, The Human Protein Atlas, GEPIA, cBioPortal, GeneMANIA, TIMER and Oncomine, in order to investigate gene expression, co-expression, clinical parameters and mutations in GINS2 in patients with breast cancer. Furthermore, the present study assessed the prognostic value of GINS2 in patients with breast cancer via the Kaplan-Meier plotter database. The results of the present study demonstrated that the mRNA levels of GINS2 were significantly higher in breast cancer tissue compared with normal tissue. In addition, high mRNA expression levels of GINS2 were associated with high Scarff-Bloom-Richardson status grades, a basal-like status and age (≤51 years); however, it was not associated with lymph node metastasis. The survival analysis revealed that increased GINS2 mRNA levels were associated with a worse prognosis for relapse-free survival in all patients with breast cancer, particularly in those with estrogen receptor-positive and progesterone receptor-positive subtypes. In addition, a positive association between the GINS2, CENPM and MCM4 genes was confirmed. The results of the present study suggest that GINS2 could be used as a potential prognostic biomarker for breast cancer. Nevertheless, further studies are necessary to confirm the effects of GINS2 on the pathogenesis and development of patients with breast cancer.
多项研究已证明GINS2在GINS复合物中在各类癌症中发挥着关键作用。然而,GINS2在乳腺癌中的分子机制和预后价值仍不清楚。本研究使用了BC-GenExMiner、COSMIC、UCSC Xena、人类蛋白质图谱、GEPIA、cBioPortal、GeneMANIA、TIMER和Oncomine,以研究乳腺癌患者中GINS2的基因表达、共表达、临床参数和突变情况。此外,本研究通过Kaplan-Meier plotter数据库评估了GINS2在乳腺癌患者中的预后价值。本研究结果表明,与正常组织相比,乳腺癌组织中GINS2的mRNA水平显著更高。此外,GINS2的高mRNA表达水平与高斯卡夫-布鲁姆-理查森分级、基底样状态和年龄(≤51岁)相关;然而,它与淋巴结转移无关。生存分析显示,GINS2 mRNA水平升高与所有乳腺癌患者无复发生存的较差预后相关,尤其是雌激素受体阳性和孕激素受体阳性亚型的患者。此外,还证实了GINS2、CENPM和MCM4基因之间存在正相关。本研究结果表明,GINS2可作为乳腺癌潜在的预后生物标志物。然而,需要进一步研究以证实GINS2对乳腺癌患者发病机制和发展的影响。